Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.

News | Heart Valve Technology

Use of Anticoagulant Drug after Aortic Valve Replacement Lowers Mortality Risk, Mayo Clinic Study Finds

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement h ...

December 12, 2023

News | Cardiovascular Clinical Studies

New Study Reveals Latest Data on Global Burden of Cardiovascular Disease

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

December 11, 2023

News | Stroke

UC Gardner Neuroscience Institute to Lead New National Stroke Study

December 8, 2023 — Ischemic stroke is the most common form of stroke in the U.S., affecting more than 690,000 people ...

December 08, 2023

The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy.

News | Cardiovascular Clinical Studies

Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix Percutaneous Mechanical Circulatory Support Technology

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

December 08, 2023

Take a look at the news making top headlines during the month of November on dicardiology.com

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

DAIC's Top 10 for November

November was a busy month with many FDA approvals and breaking clinical trial results. Take a look at the news making ...

December 05, 2023

News | Cardiovascular Education

Minneapolis Heart Institute Foundation Research Advances Understanding of Health Equity and Outcomes in Fourth-Trimester Care for Women

December 4, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

December 04, 2023

As coronary computed tomography angiography (CCTA) progresses towards becoming the primary imaging modality for not only diagnostic purposes, but also for clinical trial endpoints, there is a need to address the requirements for generating high-quality CCTA image data to ensure accurate and robust CAD assessments

Feature | Computed Tomography (CT) | By Andrew Michalski, PhD and Rohit Sood MD, PhD

From the Clinic to Pharmaceutical Clinical Trials: Considerations for using Coronary CT Angiography (CCTA) in Atherosclerotic Cardiovascular Disease (ASCVD) Clinical Trials

Coronary artery disease (CAD), also known as ischemic heart disease, is the most common heart disease with a prevalence ...

December 05, 2023

Researchers have succeeded in restoring lost brain function in mouse models of stroke using small molecules that in the future could potentially be developed into a stroke recovery therapy.

News | Stroke

New Study: Lost Brain Function Restored After Stroke

December 1, 2023 — Researchers have succeeded in restoring lost brain function in mouse models of stroke using small ...

December 01, 2023

Data from all three patients in non-randomized cohort treated with DSR 2.0 indicate safe and effective maintenance of euvolemia without the need for loop diuretics, considerable benefit in cardiorenal status and dramatic improvement in diuretic response and loop diuretic requirements up to 11 weeks post DSR treatment

News | Heart Failure

Sequana Medical Announces Positive Data from Non-randomized Cohort in US Phase 1/2a MOJAVE Study of DSR 2.0 for Treatment of Heart Failure

November 30, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure an ...

November 30, 2023

Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the first patient enrollment in the PEERLESS II study

News | Cardiovascular Clinical Studies

Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

November 29, 2023

Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced completion of enrollment in the Indian clinical trial of the TRIA polymer surgical mitral heart valve.

News | Cardiovascular Clinical Studies

Foldax Completes Enrollment in India Clinical Trial Evaluating TRIA Polymer Surgical Mitral Heart Valve

November 29, 2023 — Foldax , Inc., a leader in the development of innovative, polymer heart valves, today announced ...

November 29, 2023

Study to enroll 15 acute stroke patients across three U.S. sites

News | Stents

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

November 29, 2023

Impella Improves Survival and Heart Recovery

News | Cardiovascular Clinical Studies

First Patient Enrolled in Abiomed’s RECOVER IV Randomized Controlled Trial of Impella as a Therapy for AMI Cardiogenic Shock

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

November 28, 2023

A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation

News | Cardiovascular Clinical Studies

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

November 27, 2023

First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)

News | FDA

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

November 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

November 27, 2023